Antiemetic · Treatment of Ménière’s disease
Also known as Betahistine dihydrochloride
Betahistine is a histamine analogue. It is used to treat vertigo, tinnitus and hearing loss associated with Ménière’s disease. The precise details of its mechanism in this context are not elucidated in the provided information, beyond its classification as a histamine analogue.
Avoid unless clearly necessary—no information available.
Use only if potential benefit outweighs risk—no information available.
Reduced efficacy of betahistine due to competitive antagonism at H1 receptors. Antihistamines may also worsen vertigo in some patients.
Avoid concomitant use if possible. If co-administration is necessary, monitor for reduced efficacy of betahistine and consider alternative treatments for allergic symptoms.
Increased plasma levels of betahistine, potentially leading to increased side effects (e.g., headache, nausea, abdominal pain).
Exercise caution. Consider a lower starting dose of betahistine and monitor for increased side effects if co-administered with MAOIs. Avoid if possible.
Increased risk of drowsiness or dizziness.
Advise patients to limit alcohol intake while taking betahistine, especially if experiencing drowsiness or dizziness.
Theoretical reduction in the bronchodilator effect of beta-2 agonists, though clinically significant interactions are rare.
Monitor for reduced efficacy of beta-2 agonists, especially in patients with severe asthma or COPD. No specific dose adjustment is usually required.
Theoretical, minor interaction. Not well-documented clinically to cause significant issues.
Generally considered safe. No specific management required unless unusual symptoms occur.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, BNF·Verified: 2026-05-10 · House clinical team